Cargando…

Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms

A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD). Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the “inflammatory theory” of depression. Heightened amygdala reactivity...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Kevin A., Cooper, Ella, Voon, Valerie, Tibble, Jeremy, Cercignani, Mara, Harrison, Neil A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589643/
https://www.ncbi.nlm.nih.gov/pubmed/32457424
http://dx.doi.org/10.1038/s41380-020-0790-9
_version_ 1784598773985443840
author Davies, Kevin A.
Cooper, Ella
Voon, Valerie
Tibble, Jeremy
Cercignani, Mara
Harrison, Neil A.
author_facet Davies, Kevin A.
Cooper, Ella
Voon, Valerie
Tibble, Jeremy
Cercignani, Mara
Harrison, Neil A.
author_sort Davies, Kevin A.
collection PubMed
description A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD). Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the “inflammatory theory” of depression. Heightened amygdala reactivity (particularly to negatively valanced stimuli) is a consistent finding within MDD; can predict treatment efficacy and reverses following successful treatment. However, whether IFN-α and anti-TNF enhance/attenuate depressive symptoms through modulation of amygdala emotional reactivity is unknown. Utilizing a prospective study design, we recruited 30 patients (mean 48.0 ± 10.5 years, 21 male) initiating IFN-α treatment for Hepatitis-C and 30 (mean 50.4 ± 15.7 years, 10 male) anti-TNF therapy for inflammatory arthritis. All completed an emotional face-processing task during fMRI and blood sampling before and after their first IFN-α (4-h) or anti-TNF (24-h) injection and follow-up psychiatric assessments for 3 months of treatment. IFN-α significantly increased depression symptoms (Hamilton Depression Rating Scale HAM-D) at 4 weeks (p < 0.001) but not 4-h after first dose (p > 0.1). Conversely, anti-TNF significantly improved depressive symptoms (Hospital Anxiety and Depression Rating Scale HADS) at both 24-h (P = 0.015) and 12 weeks (p = 0.018). In support of our a-priori hypothesis, both IFN-α and anti-TNF significantly modulated amygdala reactivity with IFN-α acutely enhancing right amygdala responses to sad (compared with neutral) faces (p = 0.032) and anti-TNF conversely decreasing right amygdala reactivity (across emotional valence) (p = 0.033). Furthermore, these changes predicted IFN-induced increases in HAM-D 4 weeks later (R(2) = 0.17, p = 0.022) and anti-TNF-associated decreases in HADS at 24-h (R(2) = 0.23, p = 0.01) suggesting that actions of systemic inflammation on amygdala emotional reactivity play a mechanistic role in inflammation-associated depressive symptoms.
format Online
Article
Text
id pubmed-8589643
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85896432021-11-23 Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms Davies, Kevin A. Cooper, Ella Voon, Valerie Tibble, Jeremy Cercignani, Mara Harrison, Neil A. Mol Psychiatry Article A third of patients receiving Interferon-α (IFN-α) treatment for Hepatitis-C develop major depressive disorder (MDD). Conversely, anti-Tumor Necrosis Factor (TNF) therapies improve depression providing key empirical support for the “inflammatory theory” of depression. Heightened amygdala reactivity (particularly to negatively valanced stimuli) is a consistent finding within MDD; can predict treatment efficacy and reverses following successful treatment. However, whether IFN-α and anti-TNF enhance/attenuate depressive symptoms through modulation of amygdala emotional reactivity is unknown. Utilizing a prospective study design, we recruited 30 patients (mean 48.0 ± 10.5 years, 21 male) initiating IFN-α treatment for Hepatitis-C and 30 (mean 50.4 ± 15.7 years, 10 male) anti-TNF therapy for inflammatory arthritis. All completed an emotional face-processing task during fMRI and blood sampling before and after their first IFN-α (4-h) or anti-TNF (24-h) injection and follow-up psychiatric assessments for 3 months of treatment. IFN-α significantly increased depression symptoms (Hamilton Depression Rating Scale HAM-D) at 4 weeks (p < 0.001) but not 4-h after first dose (p > 0.1). Conversely, anti-TNF significantly improved depressive symptoms (Hospital Anxiety and Depression Rating Scale HADS) at both 24-h (P = 0.015) and 12 weeks (p = 0.018). In support of our a-priori hypothesis, both IFN-α and anti-TNF significantly modulated amygdala reactivity with IFN-α acutely enhancing right amygdala responses to sad (compared with neutral) faces (p = 0.032) and anti-TNF conversely decreasing right amygdala reactivity (across emotional valence) (p = 0.033). Furthermore, these changes predicted IFN-induced increases in HAM-D 4 weeks later (R(2) = 0.17, p = 0.022) and anti-TNF-associated decreases in HADS at 24-h (R(2) = 0.23, p = 0.01) suggesting that actions of systemic inflammation on amygdala emotional reactivity play a mechanistic role in inflammation-associated depressive symptoms. Nature Publishing Group UK 2020-05-26 2021 /pmc/articles/PMC8589643/ /pubmed/32457424 http://dx.doi.org/10.1038/s41380-020-0790-9 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Davies, Kevin A.
Cooper, Ella
Voon, Valerie
Tibble, Jeremy
Cercignani, Mara
Harrison, Neil A.
Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
title Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
title_full Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
title_fullStr Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
title_full_unstemmed Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
title_short Interferon and anti-TNF therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
title_sort interferon and anti-tnf therapies differentially modulate amygdala reactivity which predicts associated bidirectional changes in depressive symptoms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589643/
https://www.ncbi.nlm.nih.gov/pubmed/32457424
http://dx.doi.org/10.1038/s41380-020-0790-9
work_keys_str_mv AT davieskevina interferonandantitnftherapiesdifferentiallymodulateamygdalareactivitywhichpredictsassociatedbidirectionalchangesindepressivesymptoms
AT cooperella interferonandantitnftherapiesdifferentiallymodulateamygdalareactivitywhichpredictsassociatedbidirectionalchangesindepressivesymptoms
AT voonvalerie interferonandantitnftherapiesdifferentiallymodulateamygdalareactivitywhichpredictsassociatedbidirectionalchangesindepressivesymptoms
AT tibblejeremy interferonandantitnftherapiesdifferentiallymodulateamygdalareactivitywhichpredictsassociatedbidirectionalchangesindepressivesymptoms
AT cercignanimara interferonandantitnftherapiesdifferentiallymodulateamygdalareactivitywhichpredictsassociatedbidirectionalchangesindepressivesymptoms
AT harrisonneila interferonandantitnftherapiesdifferentiallymodulateamygdalareactivitywhichpredictsassociatedbidirectionalchangesindepressivesymptoms